Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research
stevepb / Pixabay

Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research

  Recently, the National Cancer Institute provided a $2.5M grant to support specialized medical research being performed at the Wake Forest Organoid Research Center (WFORCE). According to the press release,…

Continue Reading Wake Forest Baptist Comprehensive Cancer Center Receives $2.5M Grant for Organoid Research
MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC
Photo by Robina Weermeijer on Unsplash

MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC

  According to Ryan McDonald of Cure Today, the FDA recently granted Breakthrough Therapy Designation to MK-6482, an investigational HIF-2α inhibitor developed by Merck. The orally-administered drug, designed to treat…

Continue Reading MK-6482 Receives Breakthrough Therapy Designation for VHL-Related RCC
New Collaboration Will Test Live Biotherapeutics Against Different Cancers
geralt / Pixabay

New Collaboration Will Test Live Biotherapeutics Against Different Cancers

According to a story from finanznachrichten.de, the biotherapeutics company 4D pharma has recently announced a research partnership with the MD Anderson Cancer Center at the University of Texas. The goal of…

Continue Reading New Collaboration Will Test Live Biotherapeutics Against Different Cancers

New Resources Could Improve Drug Development for Fibrodysplasia Ossificans Progressiva

Ipsen has just announced that they will be acquiring Clementia Pharmaceuticals. This merging of companies is exciting for the rare community because it will strengthen the resources, knowledge-base, and overall…

Continue Reading New Resources Could Improve Drug Development for Fibrodysplasia Ossificans Progressiva

Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma

  The treatment of metastatic renal cell carcinoma (RCC) has evolved over the last ten years and investigators now look towards combination therapies to improve response rates and durability for…

Continue Reading Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma
FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
Source: Pixabay.com

FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients

According to an article from Global Banking & Financing Review, the California-based pharmaceutical company Exelixis, Inc. has announced the FDA's approval of their drug Cabometyx (cabozantinib) for patients previously diagnosed…

Continue Reading FDA Approves Drug for Previously Treated Hepatocellular Carcinoma Patients
New Combination Therapy for Renal Cell Carcinoma Gains European Approval
source: pixabay.com

New Combination Therapy for Renal Cell Carcinoma Gains European Approval

According to a story from BioPortfolio, the Bristol-Myers Squibb Company recently announced that the European Commission has recently approved the first combination treatment for renal cell carcinoma available in the…

Continue Reading New Combination Therapy for Renal Cell Carcinoma Gains European Approval